Author of

• 15209

  +

  P3.01 - Poster Session/ Treatment of Advanced Diseases – NSCLC (ID 208)

  • Event: WCLC 2015
  • Type: Poster
  • Track: Treatment of Advanced Diseases - NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)

  • 15227

    +

    P3.01-018 - Icotinib for Control of Leptomeningeal Carcinomatosis in Non-Small Cell Lung Cancer with Sensitive EGFR Mutations (ID 1410)

    09:30 - 09:30  |  Author(s): L. Gong
    • Abstract
    • Slides

    Background:
    The incidence rate of leptomeningeal carcinomatosis (LC) has been increased in advanced non-small cell lung cancer (NSCLC) patients, especially with EGFR mutations. The purpose of this study was to evaluate the efficacy of icotinib for the control of LC in NSCLC with sensitive EGFR mutations.
    
    Methods:
    Twenty-one NSCLC patients with sensitive EGFR mutations and cytologically proven LC diagnoses between 2011 and 2014 at Zhejiang Cancer Hospital were retrospectively reviewed.
    
    Results:
    Ten patients had exon 21 point mutations and eleven patients had exon 19 deletional mutations. Sixteen of 21 patients received standard dose of icotinib (125 mg/day, three times a day) after LC diagnoses. The other five patients had already used icotinib and switched to double dose of icotinib (250 mg/day, three times a day) after LC occurrence. Eight patients received intrathecal chemotherapy, and nine of them were treated with combined whole-brain radiotherapy. Eighteen of 20 patients (90.0%) showed improvement of dizziness and headache. Seventeen of 21 patients (80.9%) had an improved Eastern Cooperative Oncology Group performance status (ECOG PS) score after icotinib treatment. The median overall survival was 10.1 months (95% CI: 8.4–12.0). Univariate analysis showed that the poor ECOG PS score (PS > 2), coexisting parenchymal brain metastasis, and the taken of icotinib were unfavorable prognostic factors for patient survival.The ECOG PS scare was an only independently predictor for survival in the multivariable analysis.
    
    Conclusion:
    This study suggested that icotinib had efficacy for the control of LC in NSCLC with sensitive EGFR mutations and was well tolerated. The Further prospective study is warranted.
    
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.